Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center

Vaccine

Volumn 24, Issue 21, 2006, Pages 4582-4585

  Bergman, P J ^a,b   Camps Palau, M A ^a   McKnight, J A ^a   Leibman, N F ^a   Craft, D M ^a   Leung, C ^a   Liao, J ^a   Riviere, I ^b   Sadelain, M ^b   Hohenhaus, A E ^a   Gregor, P ^b   Houghton, A N ^b   Perales, M A ^b   Wolchok, J D ^b  

^a ANIMAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Canine; Comparative oncology; DNA vaccine; Melanoma; Xenogeneic

Indexed keywords

MELANOMA ANTIGEN; MELANOMA ANTIGEN GP75; MONOPHENOL MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DOG; DRUG DELIVERY SYSTEM; KAPLAN MEIER METHOD; MELANOMA; NONHUMAN; PRIORITY JOURNAL; VITILIGO;

ANIMALS; ANTIBODY FORMATION; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; MELANOMA; MONOPHENOL MONOOXYGENASE; VACCINES, DNA;

EID: 33747147093     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.08.027     Document Type: Article

References (29)

1. MacEwen E.G., Patnaik A.K., Harvey H.J., Hayes A.A., and Matus R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest 4 5 (1986) 397-402
2. Harvey H.J., MacEwen E.G., Braun D., Patnaik A.K., Withrow S.J., and Jongeward S. Prognostic criteria for dogs with oral melanoma. J Am Vet Med Assoc 178 6 (1981) 580-582
3. Bateman K.E., Catton P.A., Pennock P.W., and Kruth S.A. 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med 8 4 (1994) 267-272
4. Bostock D.E. Prognosis after surgical excision of canine melanomas. Vet Pathol 16 1 (1979) 32-40
5. Ramos-Vara J.A., Beissenherz M.E., Miller M.A., Johnson G.C., Pace L.W., Fard A., et al. Retrospective study of 338 canine oral melanomas with clinical, histologic, and immunohistochemical review of 129 cases. Vet Pathol 37 6 (2000) 597-608
6. Curiel-Lewandrowski C., and Atkins M.B. Immunotherapeutic approaches for the treatment of malignant melanoma. Curr Opin Invest Drugs 2 11 (2001) 1553-1563
7. Sirott M.N., Bajorin D.F., Wong G.Y., Tao Y., Chapman P.B., Templeton M.A., et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72 10 (1993) 3091-3098
8. Freeman K.P., Hahn K.A., Harris F.D., and King G.K. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). J Vet Intern Med 17 1 (2003) 96-101
9. Houghton A.N., Meyers M.L., and Chapman P.B. Medical treatment of metastatic melanoma. Surg Clin North Am 76 6 (1996) 1343-1354
10. Wolchok J.D., and Livingston P.O. Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2 4 (2001) 205-211
11. Chapman P.B., Einhorn L.H., Meyers M.L., Saxman S., Destro A.N., Panageas K.S., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17 9 (1999) 2745-2751
12. Rassnick K.M., Ruslander D.M., Cotter S.M., Al-Sarraf R., Bruyette D.S., Gamblin R.M., et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases. J Am Vet Med Assoc 218 9 (2001) 1444-1448
13. Proulx D.R., Ruslander D.M., Dodge R.K., Hauck M.L., Williams L.E., Horn B., et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 44 3 (2003) 352-359
14. Hogge G.S., Burkholder J.K., Culp J., Albertini M.R., Dubielzig R.R., Yang N.S., et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther 6 1 (1999) 26-36
15. Hogge G.S., Burkholder J.K., Culp J., Albertini M.R., Dubielzig R.R., Keller E.T., et al. Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer. Hum Gene Ther 9 13 (1998) 1851-1861
16. MacEwen E.G., Kurzman I.D., Vail D.M., Dubielzig R.R., Everlith K., Madewell B.R., et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5 12 (1999) 4249-4258
17. Dow S.W., Elmslie R.E., Willson A.P., Roche L., Gorman C., and Potter T.A. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest 101 11 (1998) 2406-2414
18. Walsh P., Gonzalez R., Dow S., Elmslie R., Potter T., Glode L.M., et al. A phase I study using direct combination DNA injections for the immunotherapy of metastatic melanoma University of Colorado Cancer Center Clinical Trial. Hum Gene Ther 11 9 (2000) 1355-1368
19. Quintin-Colonna F., Devauchelle P., Fradelizi D., Mourot B., Faure T., Kourilsky P., et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther 3 12 (1996) 1104-1112
20. Bianco S.R., Sun J., Fosmire S.P., Hance K., Padilla M.L., Ritt M.G., et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther 10 9 (2003) 726-736
21. Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., Foley R., Kruth S., Liaw P.C., et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med 19 1 (2005) 56-63
22. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282 5388 (1998) 476-480
23. Edgeworth R.L., San J.H., Rosenzweig J.A., Nguyen N.L., Boyer J.D., and Ugen K.E. Vaccine development against HIV-1: current perspectives and future directions. Immunol Res 25 1 (2002) 53-74
24. Weber L.W., Bowne W.B., Wolchok J.D., Srinivasan R., Qin J., Moroi Y., et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102 6 (1998) 1258-1264
25. Wolchok J.D., Livingston P.O., and Houghton A.N. Vaccines and other adjuvant therapies for melanoma. Hematol Oncol Clin North Am 12 4 (1998) 835-848 vii.
26. Bouchard B., Fuller B.B., Vijayasaradhi S., and Houghton A.N. Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med 169 6 (1989) 2029-2042
27. Ross H.M., Weber L.W., Wang S., Piskun G., Dyall R., Song P., et al. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. Clin Cancer Res 3 12 Part 1 (1997) 2191-2196
28. Perales M.A., Blachere N.E., Engelhorn M.E., Ferrone C.R., Gold J.S., Gregor P.D., et al. Strategies to overcome immune ignorance and tolerance. Semin Cancer Biol 12 1 (2002) 63-71
29. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9 4 (2003) 1284-1290